CN112867541B - 针对弯曲杆菌物种的抗体 - Google Patents

针对弯曲杆菌物种的抗体 Download PDF

Info

Publication number
CN112867541B
CN112867541B CN201980047394.7A CN201980047394A CN112867541B CN 112867541 B CN112867541 B CN 112867541B CN 201980047394 A CN201980047394 A CN 201980047394A CN 112867541 B CN112867541 B CN 112867541B
Authority
CN
China
Prior art keywords
thr
ser
lys
leu
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980047394.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN112867541A (zh
Inventor
法比奥·格拉西
利萨·佩鲁扎
马迪奥·皮祖托
法比奥·贝尼尼
达维德·科尔蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Research in Biomedicine
Humabs Biomed SA
Original Assignee
Institute for Research in Biomedicine
Humabs Biomed SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute for Research in Biomedicine, Humabs Biomed SA filed Critical Institute for Research in Biomedicine
Publication of CN112867541A publication Critical patent/CN112867541A/zh
Application granted granted Critical
Publication of CN112867541B publication Critical patent/CN112867541B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/121—Helicobacter (G); Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201980047394.7A 2018-07-17 2019-07-16 针对弯曲杆菌物种的抗体 Active CN112867541B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862699573P 2018-07-17 2018-07-17
US62/699,573 2018-07-17
PCT/US2019/042070 WO2020018584A2 (en) 2018-07-17 2019-07-16 Antibodies against campylobacter species

Publications (2)

Publication Number Publication Date
CN112867541A CN112867541A (zh) 2021-05-28
CN112867541B true CN112867541B (zh) 2024-08-30

Family

ID=67480448

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980047394.7A Active CN112867541B (zh) 2018-07-17 2019-07-16 针对弯曲杆菌物种的抗体

Country Status (13)

Country Link
US (1) US12297258B2 (cg-RX-API-DMAC7.html)
EP (1) EP3823727A2 (cg-RX-API-DMAC7.html)
JP (2) JP2021530237A (cg-RX-API-DMAC7.html)
KR (1) KR20210041557A (cg-RX-API-DMAC7.html)
CN (1) CN112867541B (cg-RX-API-DMAC7.html)
AU (1) AU2019306543A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021000772A2 (cg-RX-API-DMAC7.html)
CA (1) CA3105222A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190194A1 (cg-RX-API-DMAC7.html)
IL (1) IL280234A (cg-RX-API-DMAC7.html)
MX (1) MX2021000268A (cg-RX-API-DMAC7.html)
SG (1) SG11202013193XA (cg-RX-API-DMAC7.html)
WO (1) WO2020018584A2 (cg-RX-API-DMAC7.html)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
WO2005028515A1 (ja) 2003-09-24 2005-03-31 Kyowa Hakko Kogyo Co., Ltd. ヒトインスリン様成長因子に対する遺伝子組換え抗体
ES2358804T3 (es) * 2003-11-21 2011-05-13 Ace Biosciences A/S Polipéptidos de campylobacter jejuni ubicados en superficie.
GB0423681D0 (en) * 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
MX2015005304A (es) 2012-10-24 2016-04-04 Nat Res Council Canada Anticuerpo contra campylobacter jejuni y usos para los mismos.
EP2995679A4 (en) 2013-03-11 2016-12-14 Kansai Bunri Sogo Gakuen PROCESS FOR PREPARING MONOCLONAL IGA ANTIBODIES

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Characterization and antigenicity of recombinant Campylobacter jejuni flagellar capping protein FliO";H.Y. YEH 等;《JOURNAL OF MEOICAL MICROBIOLOGY》;第63卷(第Pt_4期);摘要,图4、5 *
ALI RIAZI 等."Pentavalent Single-Oomain Antibodies Reduce Campylobacter jejuni Motility and Colonization in Chickens".2013,第8卷(第12期),全文. *

Also Published As

Publication number Publication date
EA202190194A1 (ru) 2021-04-16
MX2021000268A (es) 2021-06-08
EP3823727A2 (en) 2021-05-26
IL280234A (en) 2021-03-25
US12297258B2 (en) 2025-05-13
JP2024116266A (ja) 2024-08-27
KR20210041557A (ko) 2021-04-15
WO2020018584A2 (en) 2020-01-23
WO2020018584A3 (en) 2020-04-02
SG11202013193XA (en) 2021-02-25
US20210284718A1 (en) 2021-09-16
CA3105222A1 (en) 2020-01-23
AU2019306543A1 (en) 2021-01-28
CN112867541A (zh) 2021-05-28
BR112021000772A2 (pt) 2021-04-13
JP2021530237A (ja) 2021-11-11

Similar Documents

Publication Publication Date Title
CN116063464B (zh) 冠状病毒的抗体或其抗原结合片段
CN114887053B (zh) 一种tslp相关病症治疗剂的开发和应用
CN116023478B (zh) 冠状病毒的中和抗体或其抗原结合片段
CN116194476A (zh) 针对sars-cov-2的抗体和其使用方法
CN116847864A (zh) 治疗剂和诊断剂以及其用途
WO2016002820A1 (ja) 新規抗ヒトox40リガンド抗体、及びこれを含む抗インフルエンザ薬
TW202305000A (zh) 表現抗ror1/抗cd3雙特異性抗體之溶瘤病毒
CA3194162A1 (en) Antibodies against sars-cov-2
Wang et al. Development and identification of porcine monoclonal antibodies against PEDV from single B cells
EP4568998A1 (en) B7-h3 antigen-binding molecules
US20250059260A1 (en) Methods for detecting or treating influenza infections
EP4279509A1 (en) Garp protein antibody and application thereof
HK40053364A (en) Antibodies against campylobacter species
CN112867541A (zh) 针对弯曲杆菌物种的抗体
US20240101695A1 (en) Immunoglobulin e antibody compositions and methods of use
EP4472663A1 (en) Therapeutic and diagnostic agents and uses thereof
CN116419972A (zh) 抗SARS-CoV-2抗体及其应用
WO2022132887A1 (en) Human monoclonal antibodies targeting the sars-cov-2 spike protein
US20250241953A1 (en) Tdt-specific chimeric receptors and methods of their use
WO2023156187A1 (en) High affinity antibodies against the sars-cov-2 receptor binding domain
WO2024086566A2 (en) Pan-sarbecovirus neutralizing antibodies and methods of use thereof
HK40102827A (en) Dna encoded antibodies for use against sars-cov-2
CN121241064A (zh) 与多种沙贝病毒结合的抗体
CN116745314A (zh) 针对sars-cov-2的抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40053364

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant